Moisseiev Elad, Loewenstein Anat
Dev Ophthalmol. 2017;60:165-174. doi: 10.1159/000459706. Epub 2017 Apr 20.
Diabetic macular edema (DME) is the most common cause of vision loss in diabetic patients, and its management is often a long process requiring frequent monitoring and therapeutic interventions. During the past several decades, numerous treatments have been developed for the treatment of DME. Although many of them have been found to be effective and safe, there is relatively little comparative data, and no established guidelines for the optimal treatment approach exist. In this chapter, the evolution of DME therapies is reviewed, and the current common practice patterns are discussed. Available data from clinical trials on the commonly used agents, as well as comparative studies and combination therapies are reviewed. Additionally, recent advances and novel treatment options that are currently being investigated are also discussed.
糖尿病性黄斑水肿(DME)是糖尿病患者视力丧失的最常见原因,其治疗通常是一个漫长的过程,需要频繁监测和治疗干预。在过去几十年中,已开发出多种治疗DME的方法。尽管其中许多方法已被证明有效且安全,但相对而言比较数据较少,并且不存在关于最佳治疗方法的既定指南。在本章中,将回顾DME治疗方法的演变,并讨论当前的常见实践模式。将回顾关于常用药物的临床试验的现有数据,以及比较研究和联合治疗。此外,还将讨论目前正在研究的最新进展和新的治疗选择。